Joint position statement of the International Federation of Sports Medicine (FIMS) and European Federation of Sports Medicine Associations (EFSMA) on the IOC framework on fairness, inclusion and non-discrimination based on gender identity and sex variations

Fabio Pigozzi 1,2,3, Xavier Bigard 1,4,5, Juergen Steinacker 6, Bernd Wolfarth 1,7, Victoriya Badtieva 8,9, Christian Schneider 10, Jeroen Swart 1,11, James Lee John Bilzon 1,12, Demitri Constantinou 1,13, Michiko Dohi 1,14, Luigi Di Luigi 1,15, Chiara Fossati 1,2,3, Norbert Bachl 1,16,17, Guoping Li 1,18, Theodora Papadopoulou 1,4,19, Maurizio Casasco 1,15, Dina Christina (Christa) Janse van Rensburg 1,12,21, Jean-Francois Kaux 1,23, Sandra Rozenstoka 1,24, Jose-Antonio Casajus 1,25, Irina Zelenkova 1,25, Emre Ak 1,26, Bulent Ulkar 1,27, Francisco Arroyo 1,28, Anca Ionescu 4,29, André Pedrinelli 1,30, Mike Miller 31, Patrick Singleton 31, Malav Shroff 31, Nick Webborn 32,33, James Barrett 34, Blair Hamilton 32,35, Michael Geistlinger 36, Gianfranco Beltrami 37,38, Sergio Migliorini 39, Lenka Dienstbach-Wech 40, Stéphane Bermon 41,42, Yannis P Pitsiladis 1,4,32,35, on behalf of the International Federation of Sports Medicine (FIMS) and the European Federation of Sports Medicine Associations (EFSMA).

ABSTRACT

The IOC recently published its framework on fairness, inclusion and non-discrimination based on gender identity and sex variations. This framework is drafted mainly from a human rights perspective, with less consideration for medical/scientific issues. The framework places the onus for gender eligibility and classification entirely on the International Federations (IFs), even though most will not have the capacity to implement the framework. The position of no presumption of advantage is contrary to the 2015 IOC consensus. Implementation of the 2021 framework will be a major challenge for IFs that have already recognised the inclusion of transgender or differences of sexual development (DSD) athletes using a scientific/medical solution. The potential consequences for sports that need to prioritise fairness or safety could be one of two extremes (1) exclusion of all transgender or DSD athletes on the grounds of advantage or (2) self-identification that essentially equates to no eligibility rules. Exclusion of all transgender or DSD athletes is contrary to the Olympic charter and unlawful in many countries. While having no gender eligibility rules, sport loses its meaning and near-universal support.

Key messages

What is already known

► Athletes are currently excluded from the female category in sport based on transgender or differences of sexual development status.
► The IOC published its new framework on fairness, inclusion and non-discrimination based on gender identity and sex variations in November 2021.
► The publication of this framework has generated debate and discussion in sport and exercise medicine.

Athletes should not be under pressure to undergo medical procedures or treatment to meet eligibility criteria. However, if an athlete is fully informed and consents, then it is their free choice to undergo care considered necessary for gender classification for sport to compete fairly and safely in their chosen gender. Free choice is a fundamental human right, but so is the right to fair and safe competition.
The IOC published its new framework on fairness, inclusion and non-discrimination based on gender identity and sex variations on 16 November 2021. This framework drafted mainly from a particular human rights perspective with little consideration of medical/scientific issues supersedes the 2015 IOC consensus on sex reassignment and hyperandrogenism that was concluded following a rigorous in-person IOC consensus meeting that focused on scientific and medical aspects of sex, gender, performance. The 2015 consensus was drafted with the overriding sporting objective ‘the guarantee of fair competition’ and the realisation that ‘restrictions on participation are appropriate to the extent that they are necessary and proportionate to the achievement of that objective’. The 2021 IOC framework’s position of ‘no presumption of [performance] advantage’ that states ‘until evidence determines otherwise, athletes should not be deemed to have an unfair or disproportionate competitive advantage due to their sex variations, physical appearance or transgender status’ is in stark contrast with the outcome of the 2015 IOC consensus, the scientific evidence, and the subsequent assessment of numerous sports medicine associations/commis- sions. For instance, the Sports Medicine Commission of World Rowing, also known as the World Rowing Federation (previously Fédération Internationale des Sociétés d’Aviron (FISA)), concluded that ‘the FISA Sports Medicine Commission, in acknowledgement of the scientific and medical literature, see an important role of testosterone for performance, training, and regeneration in rowing and therefore supports the listing of testosterone in the World Anti-doping Agency (WADA) prohibited list (International Standard)’.

Given the above, this joint position statement aims to present an evidence-based critique that is consistent with a more rounded view of human rights and promote discussion of this new framework, especially among those responsible for the care of athletes. This joint position statement of the International Federation of Sports Medicine (FIMS) and European Federation of Sports Medicine Associations (EFSMA) has been prepared by expert members of the respective Executive Committees and relevant Commissions, members and affiliates of the FIMS Collaborating Centres of Sports Medicine and other invited medical experts from the international sports and exercise medicine community, including Chief Medical Officers of numerous International Federations (IFs). A number of the authors of this joint position statement were also members of the 2015 IOC consensus on sex reassignment and hyperandrogenism.

NOT SCIENTIFIC OR MEDICALLY-BASED

The new IOC framework mainly focuses on a particular human rights perspective, and the scientific, biological or medical aspects are not considered. This is highlighted specifically in point 5 of the framework, which states that there should be ‘no presumption of advantage’ due to an athlete’s sex variations or transgender status. While not being named specifically in the framework but clarified in the presentation of the framework by the IOC, it is clear that this point refers to the androgenic hormone testosterone and that there should be no presumption of advantage due to high concentrations of testosterone in the male range of 9.2–31.8 nmol/L for long periods. Testosterone is well established in the literature to promote the male secondary sex characteristics and is the primary driver for the increase in muscle mass, enhanced physique and performance for athletes. High concentrations of testosterone drive an increase in fat-free mass, which is responsible for much of the sex differences in sports performance between cisgender men and cisgender women. The performance-defining qualities of testosterone are also reflected in the fact that the WADA lists testosterone as an S1 anabolic agent and ‘prohibits its use at all times’. Therefore, there is little doubt that high testosterone concentrations, either endogenous or exogenous, confer a baseline advantage for athletes in certain sports. Hence, it is clear to uphold the integrity and fairness of sport that these baseline advantages of testosterone must be recognised and mitigated, as has been called for previously.

Second, point 7.1 of the new framework mischaracterises the medical treatment of transgender athletes as a ‘medically unnecessary procedure or treatment’. Gender-affirming hormone treatment has been shown to have both positive physical and psychological effects, such as improved quality of life and mood of the transitioning individual, with the administration of exogenous virilising hormones considered a mainstay treatment for many transgender patients and importantly, medically necessary for these patients. The protocol for the treatment of trans women is to seek testosterone suppression and feminising exogenous oestralal supplement to the norms of cisgender women (testosterone 0.5–2.4 nmol/L;
Eligibility by Gender 1) A rower is eligible to compete in a men’s event or as a man in a mixed event if the gender of the rower is Male in the rower’s passport or national identity card. 2) A rower is eligible to compete in a women’s event, or as a woman in a mixed event, if: a) The gender of the rower is Female in the rower’s passport or national identity card; and b) where applicable, the rower meets the requirements of paragraph 3 below 3) Where, either: a) the rower’s gender has changed; or b) the rower has otherwise been required by the Executive Committee to establish eligibility to compete as a woman; the rower first satisfies the FISA Gender Advisory Panel that the rowers’ serum testosterone concentration has been less than 5 nmol/L continuously for a period of at least the previous 12 months and secondly meets any other requirements reasonably set by the Executive Committee. 26

Similar solutions to those implemented by World Athletics7 have been adopted by other IFs such as Union Cycliste Internationale27 and World Rowing26 and now in conflict with the IOC framework (table 1). Such conflicting guidelines, rules and recommendations will only confuse the IFs and athletes and provide legal ambiguity for lawyers to exploit when pursuing a gender-related case at the Court of Arbitration for Sport.

In another departure from the 2015 IOC consensus, the 2021 IOC framework places the responsibility for gender classification entirely on the IFs, even though most IFs will not have the capacity, resources or necessary expertise to adopt the framework. For instance, the 2021 framework requires ‘Any restrictions arising from eligibility criteria should be based on robust and peer-reviewed research that demonstrates a consistent, unfair, disproportionate competitive advantage in performance or unpredictable risk to the physical safety of other athletes’.1 The burden of proof is now on the IFs to provide ‘evidence-based’ eligibility criteria within the very narrow constraints imposed by the framework that requires ‘athletes should be allowed to compete in the category that best aligns with their self-determined gender identity’ and ‘athletes should never be pressured by an International Federation, sports organisation, or any other part (either by way of the eligibility criteria or otherwise) to undergo medically unnecessary procedures or treatment to meet eligibility criteria’.1

CONSEQUENCES

The potential consequences of these imposed constraints could be one of two unwanted extremes (1) exclusion of transgender or DSD athletes on the grounds of performance advantage or (2) self-identification that all but equates to no eligibility rules. By adopting the recent IOC framework without the possibility of necessary interventions for gender classification (the authors preferred use of the term rather than the unhelpful and emotionally charged concept of ‘unnecessary medical intervention’).
exclusion of all transgender or DSD athletes on the grounds of performance is likely in sports where safety and fairness are prioritised (eg, Athletics, Rugby, Boxing, Judo); at least during the time it will take for confirmatory research to be conducted. A recent viewpoint provided a potential roadmap for integrating trans women into the elite female category of sport. Some sports may be impacted by higher testosterone concentrations, while others may not. Safety is not an issue for sports that do not include contact with an opponent but have a physical challenge (eg, archery) and could be considered a testosterone impacted sport. Therefore, eligibility regulations would then be drawn up by the sports IF based on fair competition. Conversely, some sports do not include contact with the opponent or a physical challenge (ie, shooting) which could be considered a non-testosterone impacted sport. Therefore, the IF would then prioritise inclusion by maintaining baseline eligibility regulations necessary to uphold sporting integrity and prevent the premise of self-ID in the female category. However, we believe that these decision-making principles could be

Table 1  Selection of International Federations policies on integrating trans women and female athletes with differences of sexual development (DSD) into the female category of sport

| International Federation (eligibility criteria) | Rule |
|-------------------------------------------------|------|
| World Athletics (trans women) & World Athletics (female athletes with DSD) | The athlete must demonstrate that the concentration of testosterone in serum has been less than 5 nmol/L continuously for at least 12 months, and keep serum testosterone concentration below 5 nmol/L to maintain her eligibility. |
| USA Hockey (trans women) | A trans woman desiring to play girls competitive hockey must confirm by a medical professional that the athlete has undergone at least 1 year of testosterone suppression therapy. The athlete must additionally provide a personal statement, confirming the athlete's gender identity, and written confirmation of gender identity from a healthcare provider. |
| World Rugby (trans women) | Transgender women may not currently play women's rugby. |
| Scottish Women's Football Association (trans women) | May compete in female or mixed-sex domestic competition by providing evidence that her hormone therapy has brought her blood measured testosterone levels within the range of her affirmed gender. |
| International Tennis Federation (trans women) | The Athlete must provide a written and signed declaration, that her gender identity is female; and must demonstrate that the concentration of testosterone in serum has been less than 5 nmol/L1 continuously for at least 12 months and that she is ready, willing, and able to continue to keep it below that level for so long as she continues to compete in the female category of competition. |
| USA Gymnastics (trans women) | USAG believes that transgender and non-binary gymnasts should not be restricted from taking part in gymnastics competitions based on their gender identity. Athletes wishing to compete at the international track level must comply with the IOC guidelines for transgender athletes. |
| Union Cycliste Internationale (trans women) | A signed declaration that her gender identity is female, demonstrate that the concentration of testosterone in serum has been less than 5 nmol/L continuously for at least 12 months and she must keep her serum testosterone concentration below 5 nmol/L to maintain eligibility. |
| World Rowing (trans women) | A rower is eligible to compete in a women's event, or as a woman in a mixed event, if: a. The gender of the rower is Female in the rower's passport or national identity card and b. where applicable, the rower meets the requirements of paragraph three below. 3. Where, either: a. the rower's gender has changed; or b. the rower has otherwise been required by the Executive Committee to establish eligibility to compete as a woman; the rower first satisfies the World Rowing Gender Advisory Panel that the rowers' serum testosterone concentration has been less than 5 nmol/L continuously for a period of at least the previous 12 months and second meets any other requirements reasonably set by the Executive Committee. |
| World Rowing (female athletes with DSD) | The Executive Committee will appoint and maintain from time to time a panel of experts in the specialist areas of Gender Identification, Sex-reassignment, Hyperandrogenism, Transgender and Differences of Sexual Development (DSD) to be known as the Gender Advisory Panel. The purpose of that panel is to evaluate cases seeking a determination of gender eligibility and to provide expert advice to the Executive Director, the Executive Committee, or the Council (as the case may require) on those specialist areas. |
used for all IFs when considering the integration of trans women into the elite female competition.

The development of the 2021 IOC framework would in many countries be unlawful and against the Olympic charter that states:

“The enjoyment of the rights and freedoms set forth in this Olympic Charter shall be secured without discrimination of any kind, such as race, colour, sex, sexual orientation, language, religion, political or other opinion, national or social origin, property, birth or other status”.  

In the other extreme case of an equally undesirable consequence of having no gender eligibility rules, that is, self-identification that amounts to a free choice to compete in any gender classification, sport would lose its integrity and near-universal support. As we have seen during the COVID-19 crisis, sport is much poorer without supporters. Without rules that are perceived as fair, sport will not engage the younger generation and likely negatively impact future participation rates in the female category. As stated in the 2021 framework, athletes should never be pressured by an IF, sports organisation, or any other party to undergo any medical procedures or treatment to meet eligibility criteria. However, if an athlete is fully informed and consents, then it is their free choice to undergo ‘necessary interventions for gender classification’ to compete in the gender classification of their choice and return to the main theme of the new IOC framework, free choice is a fundamental human right.

CONCLUSIONS
The new IOC framework leaves all responsibilities to the IFs, whereas the authors believe the IOC should provide direction to the IFs. The IOC framework only deals with this important issue from a particular human rights perspective, yet this must be seen in a more rounded human rights perspective and is also a medical and scientific matter. The authors would like to see further discussion and consultation with all stakeholders leading to a balanced framework that protects the rights of all athletes and gives IFs the tools they need to ensure inclusion and fairness.

Author affiliations
1International Federation of Sports Medicine (FIMS), Lausanne, Switzerland
2Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, Rome, Italy
3Villa Stuart Sport Clinic, FIFA Medical Center of Excellence, Rome, Italy
4European Federation of Sports Medicine Associations (EFSMA), Lausanne, Switzerland
5Union Cycliste Internationale (UCI), Aigle, Switzerland
6Division of Sports and Rehabilitation Medicine, Department of Internal Medicine, Ulm University Hospital, Ulm, Germany
7Department of Sports Medicine, Humboldt University and Charité University School of Medicine, Berlin, Germany
8Moscow Research and Practical Center for Medical Rehabilitation, Restorative and Sports Medicine, Moscow Healthcare Department, Moscow, Russian Federation
9I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow, Russian Federation
10Orthopaedic Center Theresie, Moscow, Germany
11Health through Physical Activity, Lifestyle and Sport Research Centre (HPALS), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
12Department for Health, University of Bath, Bath, UK
13Centre for Exercise Science and Sports Medicine, University of the Witwatersrand, Johannesburg, South Africa
14Sports Medical Center, Japan Institute of Sport Sciences, Tokyo, Japan
15Unit of Endocrinology, Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, Rome, Italy
16Institute of Sports Science, University of Vienna, Vienna, Austria
17Austrian Institute of Sports Medicine, Vienna, Austria
18National Institute of Sports Medicine, Beijing, China
19Defence Medical Rehabilitation Centre, Stanford Hall, Loughborough, UK
20FIMS Collaborating Centre of Sports Medicine, Institute of Sports Medicine in Milan (Istituto di Medicina dello Sport di Milano), Milano, Italy
21Section Sports Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
22Medical Board Member, World Netball, Manchester, UK
23Sports2, Liège University and University Hospital of Liège, Liège, Belgium
24FIMS Collaborative Centre of Sports Medicine, Sports laboratory, Riga, Latvia
25GENUD research group, FIMS Collaborating Center of Sports Medicine, Department of Physiatry and Nursing, University of Zaragoza, Zaragoza, Spain
26FIMS Collaborating Center of Sports Medicine, Gloria Sports Arena Belek, Antalya, Turkey
27Sports Medicine Department, Faculty of Medicine, Ankara University, Ankara, Turkey
28FIMS Collaborating Center of Sports Medicine, Guadalajara, Mexico
29Sports Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
30Department of Orthopaedics, University of São Paulo Medical School, São Paulo, Brazil
31World Olympians Association (WOA), Lausanne, Switzerland
32School of Sport and Health Sciences, University of Brighton, Eastbourne, UK
33Medical Committee, International Paralympic Committee (IPC), Bonn, Germany
34The Gender Identity Clinic Tavistock and Portman NHS Foundation Trust, London, UK
35Centre for Stress and Age-related Disease, University of Brighton, Brighton, UK
36Department of Public, International and European Law, Unit International Law, University of Salzburg, Salzburg, Austria
37Medical Commission, World Baseball Softball Confederation, Pully, Switzerland
38Faculty of Sport Sciences, University of Parma, Parma, Italy
39World Triathlon Medical, World Triathlon, Lausanne, Switzerland
40Department of Orthopaedics, Spine and Trauma Surgery, University of Salzburg, Salzburg, Austria
41Medical Committee, World Baseball Softball Confederation, Pully, Switzerland
42LAMHESS, Université Côte d’Azur, Nice, France
43Sports Medicine Department, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain
44Department of Physiatry and Nursing, University of Zaragoza, Zaragoza, Spain
45World Athletics, Health and Science Department, Monaco
46Centre of Excellence in Exercise Science, University of Pretoria, Pretoria, South Africa
47Unit of Endocrinology, Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, Rome, Italy
48Villa Stuart Sport Clinic, FIFA Medical Center of Excellence, Rome, Italy
49International Federation of Sports Medicine (FIMS), Lausanne, Switzerland
50Department of Orthopaedics, Spine and Trauma Surgery, Hospital zum Heiligen Geist Frankfurt, Frankfurt, Germany
51School of Sport and Health Sciences, University of Brighton, Eastbourne, UK
52Medical Committee, International Paralympic Committee (IPC), Bonn, Germany
53The Gender Identity Clinic Tavistock and Portman NHS Foundation Trust, London, UK
54Centre for Stress and Age-related Disease, University of Brighton, Brighton, UK
55Department of Public, International and European Law, Unit International Law, University of Salzburg, Salzburg, Austria
56Medical Commission, World Baseball Softball Confederation, Pully, Switzerland
57Faculty of Sport Sciences, University of Parma, Parma, Italy
58World Triathlon Medical, World Triathlon, Lausanne, Switzerland
59Department of Orthopaedics, Spine and Trauma Surgery, University of Salzburg, Salzburg, Austria
60Medical Committee, World Baseball Softball Confederation, Pully, Switzerland
61World Athletics, Health and Science Department, Monaco
62LAMHESS, Université Côte d’Azur, Nice, France

Twitter Blair Hamilton @BlairH_PhD
Contributors All authors have contributed significantly to the preparation of this viewpoint and fully share its contents.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not applicable.
Ethics approval This study does not involve human participants.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
ORCID iDs
Fabio Pigozzi http://orcid.org/0000-0001-5808-9405
Juergen Steinacker http://orcid.org/0000-0001-8901-9450
Bernd Wolfarth http://orcid.org/0000-0001-6501-3003
Victoria Badtieva http://orcid.org/0000-0003-4291-679X

Pigozzi F, et al. BMJ Open Sp Ex Med 2022;8:e001273. doi:10.1136/bmjsem-2021-001273

Open access
REFERENCES
1. International Olympic Committee. Framework on fairness, inclusion and non-discrimination on the basis of gender identity and sex variations, 2021. Available: https://stillmed.olympics.com/media/Documents/News/2021/11/IOC-Framework-Fairness-Inclusion-Non-discrimination-2021.pdf

2. International Olympic Committee. Consensus meeting on sex reassignment and hyperandrogenism November 2015, 2015. Available: https://stillmed.olympics.com/Documents/Commissions/pdfFiles/Medical_commission/2015-11_ioc_consensus_meeting_on_sex_reassignment_and_hyperandrogenism-en.pdf

3. Handelsman DJ, Hirschberg AL, Berman S. Circulating testosterone as the hormonal basis of sex differences in athletic performance. Endocr Rev 2018;39:803–29.

4. Handelsman DJ, Berman S. Detection of testosterone doping in female athletes. Drug Test Anal 2019;11:1166–71.

5. Hamilton BR, Lima G, Barrett J. Integrating Transwomen and female athletes with differences of sex development (DSD) into elite competition: the FIMS 2021 consensus statement. Sports Med 2021;51.

6. World Athletics. Eligibility regulations for the female classification (athletes with differences of sex development), 2019. Available: https://www.worldathletics.org/about-iaaf/documents/book-of-rules

7. World Athletics. Eligibility regulations transgender athletes, 2019. Available: https://www.worldathletics.org/about-iaaf/documents/book-of-rules

8. World Rugby. World rugby transgender guideline, 2020. Available: https://playerwellfare.worldrugby.org/?documentId=231

9. USA Gymnastics. USA gymnastic policy for transgender inclusion, 2020. Available: https://usagym.org/PDFs/About%20USA%20Gymnastics/transgender_policy.pdf

10. International Tennis Federation. Transgender policy, 2018. Available: https://www.itftennis.com/media/2163/itf-transgender-policy.pdf

11. Scottish Womens Football Association. Transgender and transsexual policy, 2019. Available: https://scotwomensfootball.com/wp-content/uploads/2019/03/SWF-Policy-Transgender-People-Playing-in-SWF-FINAL.pdf

12. Steinacker JM, Koubaa D, Nielsen HB, et al. Statement of FISA sports medicine Commission: biological effects of testosterone. J Sports Med 2020;51.

13. NHS. Testosterone, 2020. Available: https://www.gloshospitals.nhs.uk/our-services/services-we-offer/pathology/tests-and-investigations/testosterone/

14. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987;8:1–28.

15. Institute of Medicine, Board on Health Sciences Policy, Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Testosterone and aging: clinical research directions. National Academies Press, 2004.

16. Nickerson BS, McLester CN, McLester JR, et al. Relative accuracy of anthropometric-based body fat equations in males and females with varying BMI classifications. Clin Nutr ESPEN 2020;35:136–40.

17. World Anti-Doping Agency. What is prohibited/prohibited-at-all-times/anabolic-agents

18. Hamilton BR, Martinez-Patiño MJ, Barrett J, et al. Response to the United nations human rights Council’s report on race and gender discrimination in sport: an expression of concern and a call to Prioritise research. Sports Med 2021;51:839–42.

19. Hamilton BR, Guppy FM, Barrett J, et al. Integrating transwomen athletes into elite competition: the case of elite archery and shooting. Eur J Sport Sci 2021;21:1500–9.

20. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. J Sex Med 2012;9:531–41.

21. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012;9:2641–51.

22. Unger CA. Hormone therapy for transgender patients. Transl Androl Urol 2016;5:877–84.

23. Coleman E. Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People: An Introduction. In: Principles of gender-specific medicine. Elsevier, 2017: 69–75.

24. Nickerson BS, McLester CN, McLester JR, et al. Cross-sex hormone therapy in transgender persons. N Engl J Med 2019;381:2451–60.

25. Klein DA, Paradise SL, Reeder RM. Amenorrhea: a systematic approach to diagnosis and management. Am Fam Physician 2019;100:39–48.

26. World Rowing Federation. Rule 15 and Bye law to rule 15-Men’s and Women’s Events, 2020. Available: www.worldrowing.com

27. Union Cycliste Internationale, Part 13 medical rules: chapter V eligibility regulations for transgender athletes, 2020. Available: https://archives.fcioc.org/docs/default-source/rules-and-regulations/part-xiii-medical-rules-01.03.2020.pdf

28. International Olympic Committee. Olympic charter, 2020. Available: www.olympic.org/docs/documents\olympic-charter

29. USA Hockey. Transgender athlete eligibility policy, 2019. Available: https://cdn3.sportngin.com/attachments/document/8a0b-17686565/USA_Hockey_Transgender_Athlete_Eligibility_Policy.pdf